8 recruiting, 4 completed, 3 enrolling by invitation, 2 not yet recruiting. 13 Not applicable, 4 Phase 2, 1 Early Phase 1, 1 Phase 1.
Follow Stimulant Use Disorder: new trials by email Literature Review of Stimulant Use Disorder trials Research Report on Stimulant Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R33 Phase Clinical Trial) PATH (Peer Advanced Training for total Health) - Burnout, Secondary Trauma | Not applicable | Enrolling by invitation | Chestnut Health Systems | 200 | 2026-10-12 | 2026-10-27 |
| Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study Emotional Brain Training, Standard addiction counseling and medical therapy - Cannabis Use Disorder, Stimulant Use Disorder | Not applicable | Not yet recruiting | Loma Linda University | 54 | 2026-08-01 | 2026-04-23 |
| RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry DynamiCare, Patient Navigation (PN) - HIV, Stimulant Use Disorder | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 40 | 2026-06-01 | 2026-06-15 |
| Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder Repetitive transcranial magnetic stimulation (rTMS), Sham rTMS - Stimulant Use Disorder | Not applicable | Recruiting | VA Office of Research and Development | 106 | 2026-05-01 | 2026-09-11 |
| LDART for Stimulant Use Disorder LDART, Psychoeducational booklet - Stimulant Use Disorder, Cocaine Use Disorder | Not applicable | Enrolling by invitation | Yale University | 80 | 2026-04-29 | 2026-05-01 |
| Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails Cognitive Processing Therapy (CPT), Written Exposure Therapy (WET) - Post-traumatic Stress Disorder (PTSD), Post-traumatic Stress Symptoms | Not applicable | Enrolling by invitation | University of Arkansas | 338 | 2026-01-20 | 2026-06-18 |
| Smartphone Services for Stimulant Use Disorder Smartphone digital therapeutic system - Stimulant Use Disorder | Not applicable | Recruiting | DynamiCare Health | 270 | 2025-06-24 | 2025-07-29 |
| reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA) reSET, Standard of care - Stimulant Use Disorder, People Living With HIV | Not applicable | Recruiting | University of Miami | 260 | 2025-03-04 | 2026-08-17 |
| PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study PEX010-Assisted Therapy, PEX010(01) - Stimulant Use Disorder | Phase 2 | Not yet recruiting | Filament Health Corp. | 86 | 2025-01-01 | 2024-10-30 |
| Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder closed-loop-peak, Open-loop, closed-loop-trough - Stimulant Use Disorder | Phase 1 | Recruiting | University of Minnesota | 50 | 2024-12-01 | 2026-09-01 |
| Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use Integrated Infectious Diseases and Substance Use Disorder Clinic (IC) - Opioid Use Disorder, Injection Related Infections | Not applicable | Recruiting | Elana Rosenthal | 304 | 2024-10-01 | 2026-11-10 |
| Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder SUVO, TAU - Stimulant Use Disorder | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | 20 | 2024-07-25 | 2025-09-05 |
| Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment Mirtazapine, Placebo - Stimulant Use Disorder | Phase 2 | Recruiting | Washington State University | 60 | 2024-06-17 | 2026-07-02 |
| Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine) n-acetylcysteine, Hydromorphone, Placebo n-acetylcystine - Cocaine Use Disorder, Opioid Use Disorder | Early Phase 1 | Completed | William Stoops | 12 | 2022-12-15 | 2026-05-05 |
| Suvorexant for Opioid/Stimulant Co-use Suvorexant (dual orexin receptor antagonist), Placebo - Opioid Use Disorder, Stimulant Use Disorder | Phase 2 | Completed | Johns Hopkins University | 20 | 2022-12-01 | 2025-12-23 |
| Contingency Management for Opioid and Stimulant Use Disorders in Primary Care Contingency Management - Opioid Use Disorder, Stimulant Use Disorder | Not applicable | Active not recruiting | University of Minnesota | 56 | 2022-06-15 | 2026-11-12 |
| Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations Patient Navigator, Mobile Health Unit - Opioid Use Disorder, Infectious Disease | Not applicable | Completed | Yale University | 601 | 2022-03-31 | 2026-09-21 |
| rTMS for Stimulant Use Disorders rTMS, Sham (Placebo) - Cocaine Use Disorder, Methamphetamine Abuse | Not applicable | Completed | Medical University of South Carolina | 129 | 2022-02-04 | 2025-07-03 |
| Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation Repetitive transcranial magnetic stimulation (rTMS) - Stimulant Use Disorder, Substance-related Disorders | Not applicable | Terminated | VA Office of Research and Development | 30 | 2021-02-05 | 2025-08-29 |
Opioid-Related Disorders (8) · Substance-Related Disorders (8) · Cocaine-Related Disorders (2) · Alcoholism (1) · Burnout, Psychological (1) · Chemically-Induced Disorders (1) · Communicable Diseases (1) · Compassion Fatigue (1) · Narcotic-Related Disorders (1) · Risk Reduction Behavior (1) · Stress Disorders, Post-Traumatic (1) · Tobacco Use Disorder (1) · Wounds and Injuries (1)
Mental Disorders (13) · Chemically-Induced Disorders (12) · Narcotic-Related Disorders (7) · Substance-Related Disorders (5) · Behavior (2) · Pathological Conditions, Signs and Symptoms (2) · Alcohol-Related Disorders (1) · Behavioral Symptoms (1) · Disease Attributes (1) · Fatigue (1) · Infections (1) · Mental Fatigue (1) · Occupational Stress (1) · Pathologic Processes (1) · Signs and Symptoms (1)
Transcranial Magnetic Stimulation (3) · Patient Navigation (2) · Acetylcysteine (1) · Hydromorphone (1) · Mirtazapine (1) · Mobile Health Units (1) · Orexin Receptor Antagonists (1) · Standard of Care (1) · suvorexant (1)
University of Minnesota (2) · VA Office of Research and Development (2) · Yale University (2) · Chestnut Health Systems (1) · DynamiCare Health (1) · Elana Rosenthal (1) · Filament Health Corp. (1) · Johns Hopkins University (1) · Loma Linda University (1) · Medical University of South Carolina (1) · The University of Texas Health Science Center, Houston (1) · University of Arkansas (1) · University of Miami (1) · University of Texas Southwestern Medical Center (1) · Washington State University (1)
United States (18)
Jong H. Yoon, MD (2) · Alexander Optiz (1) · Ank Nijhawan, MD (1) · Carla J Rash, PhD (1) · David R Gastfriend, MD (1) · Dennis P Watson, PhD (1) · Elana Rosenthal, MD (1) · Heather Webber, PhD (1) · Jennifer Ellis, Ph.D. (1) · Jose Szapocznik, PhD (1) · Kathleen T Brady, MD PHD (1) · Li Yan McCurdy, PhD (1) · Madhukar Trivedi, MD (1) · Robert Levy, MD (1) · Sandra A Springer, MD (1)
PMID 35428213, PMID 40336040, PMID 40478391, PMID 41776656, PMID 41950275
I01RD000693 (1), R01DA055563 (1), R33DA049130 (1), R33DA059947 (1), R33DA061340 (1), R44DA059519 (1), U01DA053039 (1), UG1DA013727 (1)